Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,510
datasets available to search
ShareScore release 0.9.0
Dataset results
1,510 results for “Liver disease”
Effects of SAMe in Patients With Alcoholic Liver Disease
ClinicalTrials.gov study NCT00573313. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
ClinicalTrials.gov study NCT03946449. IPD Sharing: NO. Countries: 3. Publications: 1.
Fucoidan Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD)
ClinicalTrials.gov study NCT02875392. IPD Sharing: NO. Countries: 1. Publications: 1.
An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome
ClinicalTrials.gov study NCT02117713. IPD Sharing: NO. Countries: 2. Publications: 0.
Effect of the Combined Application of Cynara Scolymus, Silybum Marianum, Curcuma Longa, and Glycyrrhiza Glabra in Improving Metabolic Associated Fatty Liver Disease : a Randomized Clinical Trial
ClinicalTrials.gov study NCT06798948. IPD Sharing: NO. Countries: 1. Publications: 4.
Methacetin Breath Test in Patients With Liver Disease Secondary to Heart Disease
ClinicalTrials.gov study NCT04176458. IPD Sharing: NO. Countries: 1. Publications: 1.
Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)
ClinicalTrials.gov study NCT02369536. IPD Sharing: NO. Countries: 1. Publications: 1.
Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency
ClinicalTrials.gov study NCT01379469. IPD Sharing: YES. Countries: 1. Publications: 44.
Phase 2, Pharmacokinetics Study of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease
ClinicalTrials.gov study NCT00861601. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Treatment of Non Alcoholic Fatty Liver Disease With n-3 Fatty Acids
ClinicalTrials.gov study NCT00760513. IPD Sharing: Not stated. Countries: 1. Publications: 12.
Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease
ClinicalTrials.gov study NCT03696797. IPD Sharing: NO. Countries: 1. Publications: 40.
MERFISH and snRNAseq analysis of healthy and disease human liver
Open the record for dataset details and reuse information.
Association of fat-to-muscle ratio with non-alcoholic fatty liver disease: a single-centre retrospective study
Open the record for dataset details and reuse information.
PEMT-mediated phospholipid imbalance promotes age-associated metabolic dysfunction-associated steatotic liver disease progression
Open the record for dataset details and reuse information.
Non-alcoholic fatty liver disease animal models database
Open the record for dataset details and reuse information.
Data from: Steatotic liver disease induced by TCPOBOP-activated hepatic constitutive androstane receptor: Primary and secondary gene responses with links to disease progression
Open the record for dataset details and reuse information.
Transcriptomic cross-species analysis of chronic liver disease reveals consistent regulation between humans and mice
<p>Data used to analyse chronic and acute liver disease in mice and human as described in <a href="https://doi.org/10.1002/hep4.1797">Holland et al. 2021</a>.</p> <p>Corresponding code is available on <a href="https://github.com/saezlab/liver-disease-atlas">GitHub</a>.</p>
Precancerous liver diseases do not cause increased mutagenesis in liver stem cells
<p>VCF files after variant calling using the HMF pipeline (v4.8) on bam files downloaded from PCAWG as well as from whole genome sequencing of intrahepatic cholangiocyte organoids.</p>
Dataset related to article "Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases"
<p>This record contains data related to article “Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases”</p> <p>The purpose of this study was to evaluate the efficacy and safety of the Moderna-1273 mRNA vaccine for SARS-CoV-2 in patients with immune-mediated diseases under different treatments. Anti-trimeric spike protein antibodies were tested in 287 patients with rheumatic or autoimmune diseases (10% receiving mycophenolate mofetil, 15% low-dose glucocorticoids, 21% methotrexate, and 58% biologic/targeted synthetic drugs) at baseline and in 219 (76%) 4 weeks after the second Moderna-1273 mRNA vaccine dose. Family members or caretakers were enrolled as the controls. The neutralizing serum activity against SARS-CoV-2-G614, alpha, and beta variants in vitro and the cytotoxic T cell response to SARS-CoV-2 peptides were determined in a subgroup of patients and controls. Anti-SARS-CoV-2 antibody development, i.e., seroconversion, was observed in 69% of the mycophenolate-treated patients compared to 100% of both the patients taking other treatments and the controls (<em>p</em> &lt; 0.0001). A dose-dependent impairment of the humoral response was observed in the mycophenolate-treated patients. A daily dose of &gt;1 g at vaccination was a significant risk factor for non-seroconversion (ROC AUC 0.89, 95% CI 0.80-98, <em>p</em> &lt; 0.0001). Moreover, in the seroconverted patients, a daily dose of &gt;1 g of mycophenolate was associated with significantly lower anti-SARS-CoV-2 antibody titers, showing slightly reduced neutralizing serum activity but a comparable cytotoxic response compared to other immunosuppressants. In non-seroconverted patients treated with mycophenolate at a daily dose of &gt;1 g, the cytotoxic activity elicited by viral peptides was also impaired. Mycophenolate treatment affects the Moderna-1273 mRNA vaccine immunogenicity in a dose-dependent manner, independent of rheumatological disease.</p> <p>.</p>
Oral lipid-based treatments for chronic liver disease: from formulation characterization to in vitro assays mimicking pathological conditions
<p>Details to the statistics for the Chapters 3 and 4 of the doctoral dissertation: "Oral lipid-based treatments for chronic liver disease: from formulation characterization to <em>in vitro</em> assays mimicking pathological conditions"</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.